Corcept Therapeutics CORT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's additional paid-in capital?
- Corcept Therapeutics (CORT) reported additional paid-in capital of $1B in Q1 2026.
- How has Corcept Therapeutics's additional paid-in capital changed year-over-year?
- Corcept Therapeutics's additional paid-in capital increased by 16.1% year-over-year, from $862.87M to $1B.
- What is the long-term trend for Corcept Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Corcept Therapeutics's additional paid-in capital has grown at a 13.4% compound annual growth rate (CAGR), from $516.14M to $968.6M.
- What does additional paid-in capital mean?
- Capital received from shareholders above the par value of the stock.
- How do you interpret additional paid-in capital?
- An increase indicates successful equity financing or the exercise of employee stock options.
- How does additional paid-in capital compare across companies?
- Standard for all public companies; reflects historical equity fundraising success.